hihingiin ang isa
Stevens Capital Closes Out Position in Eli Lilly
Stevens Capital Management LP has completely exited its position in Eli Lilly, selling all 12,036 shares in Q2 2025 for approximately $9.94 million. Following this sale, the fund's top holdings include Strategy ($35.09 million), CME Group ($20.69 million), and Apple ($19.38 million). Eli Lilly's stock has underperformed the S&P 500 by 38.3 percentage points over the past year, with a total return of -23.1%. The company, valued at $658.15 billion, continues to compete in the weight-loss drug market against Novo Nordisk.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
